$323.40
2.85% today
Nasdaq, Nov 06, 10:00 pm CET
ISIN
US45784P1012
Symbol
PODD

Insulet Corporation Stock price

$314.44
+2.75 0.88% 1M
+55.65 21.50% 6M
+53.37 20.44% YTD
+73.12 30.30% 1Y
+11.05 3.64% 3Y
+58.76 22.98% 5Y
+282.74 891.92% 10Y
+298.48 1,870.18% 20Y
Nasdaq, Closing price Wed, Nov 05 2025
-5.83 1.82%

New AI Insights on Insulet Corporation Insights AI Insights on Insulet Corporation

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$22.1b
Enterprise Value
$22.5b
Net debt
$406.8m
Cash
$992.9m
Shares outstanding
70.4m
Valuation (TTM | estimate)
P/E
94.1 | 66.2
P/S
9.4 | 8.3
EV/Sales
9.6 | 8.4
EV/FCF
58.9
P/B
15.1
Financial Health
Equity Ratio
39.2%
Return on Equity
34.5%
ROCE
16.6%
ROIC
14.9%
Debt/Equity
1.0
Financials (TTM | estimate)
Revenue
$2.4b | $2.7b
EBITDA
$494.1m | $607.8m
EBIT
$407.3m | $462.7m
Net Income
$236.1m | $334.5m
Free Cash Flow
$382.4m
Growth (TTM | estimate)
Revenue
26.0% | 29.2%
EBITDA
41.9% | 56.0%
EBIT
49.4% | 49.8%
Net Income
-40.3% | -20.0%
Free Cash Flow
109.7%
Margin (TTM | estimate)
Gross
70.7%
EBITDA
20.9% | 22.7%
EBIT
17.3%
Net
10.0% | 12.5%
Free Cash Flow
16.2%
More
EPS
$3.3
FCF per Share
$5.4
Short interest
3.5%
Employees
4k
Rev per Employee
$530.0k
Show more

Is Insulet Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Insulet Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a Insulet Corporation forecast:

29x Buy
88%
4x Hold
12%

Analyst Opinions

33 Analysts have issued a Insulet Corporation forecast:

Buy
88%
Hold
12%

Financial data from Insulet Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2,360 2,360
26% 26%
100%
- Direct Costs 690 690
19% 19%
29%
1,669 1,669
29% 29%
71%
- Selling and Administrative Expenses 1,013 1,013
24% 24%
43%
- Research and Development Expense 249 249
22% 22%
11%
494 494
42% 42%
21%
- Depreciation and Amortization 87 87
15% 15%
4%
EBIT (Operating Income) EBIT 407 407
49% 49%
17%
Net Profit 236 236
40% 40%
10%

In millions USD.

Don't miss a Thing! We will send you all news about Insulet Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Insulet Corporation Stock News

Neutral
Seeking Alpha
about 4 hours ago
Insulet Corporation ( PODD ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Clare Trachtman - Vice President of Investor Relations Ashley McEvoy - CEO, President & Director Flavia Pease - Executive VP & CFO Eric Benjamin - Executive VP & COO Conference Call Participants Robert Marcus - JPMorgan Chase & Co, Research Division David Roman - Goldman Sachs Group, Inc., Resea...
Positive
Reuters
about 10 hours ago
Medical device maker Insulet on Thursday posted third-quarter results that surpassed Wall Street's expectations on strong demand for its wearable insulin pumps, which eliminate the need for daily injections.
Neutral
Business Wire
about 11 hours ago
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended September 30, 2025. Third Quarter Financial Highlights: Revenue of $706.3 million, increased 29.9%, or 28.2% in constant currency1, and exceeded the ...
More Insulet Corporation News

Company Profile

Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Head office United States
CEO Ashley McEvoy
Employees 3,900
Founded 2000
Website www.omnipod.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today